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Summary
Background The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has 
unknown effects on overall population mortality. Previous models of population mortality are based on death over 
days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated 
information on high-risk conditions or their longer-term baseline (pre-COVID-19) mortality. We estimated the excess 
number of deaths over 1 year under different COVID-19 incidence scenarios based on varying levels of transmission 
suppression and differing mortality impacts based on different relative risks for the disease.
Methods In this population-based cohort study, we used linked primary and secondary care electronic health records 
from England (Health Data Research UK–CALIBER). We report prevalence of underlying conditions defined by Public 
Health England guidelines (from March 16, 2020) in individuals aged 30 years or older registered with a practice 
between 1997 and 2017, using validated, openly available phenotypes for each condition. We estimated 1-year mortality 
in each condition, developing simple models (and a tool for calculation) of excess COVID-19-related deaths, assuming 
relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared with background mortality) of 1·5, 2·0, 
and 3·0 at differing infection rate scenarios, including full suppression (0·001%), partial suppression (1%), mitigation 
(10%), and do nothing (80%). We also developed an online, public, prototype risk calculator for excess death estimation.
Findings We included 3 862 012 individuals (1 957 935 [50·7%] women and 1 904 077 [49·3%] men). We estimated that 
more than 20% of the study population are in the high-risk category, of whom 13·7% were older than 70 years and 
6·3% were aged 70 years or younger with at least one underlying condition. 1-year mortality in the high-risk population 
was estimated to be 4·46% (95% CI 4·41–4·51). Age and underlying conditions combined to influence background 
risk, varying markedly across conditions. In a full suppression scenario in the UK population, we estimated that there 
would be two excess deaths (vs baseline deaths) with an RR of 1·5, four with an RR of 2·0, and seven with an RR of 
3·0. In a mitigation scenario, we estimated 18 374 excess deaths with an RR of 1·5, 36 749 with an RR of 2·0, and 
73 498 with an RR of 3·0. In a do nothing scenario, we estimated 146 996 excess deaths with an RR of 1·5, 293 991 with 
an RR of 2·0, and 587 982 with an RR of 3·0.
Interpretation We provide policy makers, researchers, and the public a simple model and an online tool for 
understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying 
condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as 
sustained efforts to target those at highest risk because of underlying conditions with a range of preventive 
interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.
Funding National Institute for Health Research University College London Hospitals Biomedical Research Centre, 
Health Data Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Excess deaths from the coronavirus disease 2019 
(COVID-19) pandemic might arise both in those infected 
(direct effects), as well as those affected (indirectly, not 
infected) by altered access to health services; the physical, 
psychological, and social effects of distancing; and 
economic changes. Understanding the effect of COVID-19 
on mortality during this emergency requires modelling of 
an infectious disease, as well as wider medical and 
societal changes. One way of estimating and monitoring 
excess mortality is to compare observed numbers of 
deaths with those expected based on the background 
(pre-COVID-19) mortality risks in the population.1
One model of the population mortality impact of 
COVID-19 is based on age-stratified death rates over days 
in infected patients, but excludes prevalence of underlying 
conditions, their differing pre-COVID-19 background long-
term mortality risks, or the additional risk associated with 
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COVID-19.2 Few reports of excess deaths beyond specific 
high-risk populations have been published3,4 (most deaths 
have occurred in people with underlying health conditions 
or those of older ages5–7). This situation is changing, with 
severe infections being treated in younger patients with 
COVID-19 who do not have underlying conditions.8 Case 
fatality rates for COVID-19 vary from 0·27% to 10%,9 
possibly explained by differing demography, testing strat-
egies, and prev alence of under lying conditions. The UK 
has relatively high case fatality rates (8·2%), but mortality 
rates are unknown at this stage of the pandemic because 
testing is more common among sicker patients who are 
admitted to hospital (the context where most testing has 
been done) rather than milder cases. On April 14, the Office 
for National Statistics reported 6000 excess deaths 
registered in the week March 28 to April 3, 2020, of which 
about 2500 deaths did not have COVID-19 recorded on the 
death certificates, providing the first indication of indirect 
effects of the pandemic on mortality.10
Physical distancing and other strategies focus on high-
risk groups, with US Centers for Disease Control and 
Prevention specifying “older adults, and people who have 
serious chronic medical conditions such as heart disease, 
diabetes and lung disease”.11 On March 16, 2020, the UK 
Government announced that particular subgroups are at 
high risk from COVID-19,12 and recommended stringent 
distancing measures, telling people how to stay away from 
others. On March 22, 2020, the Government announced 
that 1·5 million ”extremely vulnerable” people in England 
with underlying conditions (including severe chronic 
obstructive pulmonary disease [COPD]) should ”shield” 
for 12 weeks, but did not explain how these conditions 
were selected.13 The UK Government did not implement 
full suppression (during which only key workers are likely 
to be exposed) until March 23, 2020. Up to that date, people 
were still in close proximity in work and public places.
Here, we provide estimates of 1-year mortality by 
underlying conditions to understand the broader health 
impact of COVID-19. Our objectives were to provide the 
research and policy community and public with par-
ameters (prevalence and background pre-COVID-19 
1-year mortality risk by age and underlying conditions) to 
assist modelling; and to provide initial estimates of the 
excess COVID-19-related deaths over a 1-year period 
based on differing rates and relative levels of impact of 
infection. We define COVID-19-related mortality as both 
direct and indirect effects of the pandemic.
Methods
Study design and data sources
This was a population-based cohort study, done with 
clinical research using linked bespoke studies and 
electronic health records (CALIBER), an open research 
platform with validated, reusable definitions of several 
hundred underlying conditions.14,15 It links electronic 
health records from different data sources (via UK 
unique individual identification data and National Health 
Service [NHS] numbers), including primary care (Clinical 
Practice Research Datalink-GOLD), hospital care (Hospital 
Episodes Statistics), and death registry (Office of National 
Statistics). Nearly all (>99%) of the English population has 
general practice registration. CALIBER has been shown to 
be representative of the general population in terms of 
sociodemographic characteristics and overall mortality. 
Approval for the study was granted by the Independent 
Scientific Advisory Committee (20_074R) of the Medicines 
and Healthcare products Regulatory Agency in the UK in 
accordance with the Declaration of Helsinki.
Research in context
Evidence before this study
We searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome 
Open Research for peer-reviewed articles, preprints, and 
research reports on mortality and comorbidities at baseline in 
coronavirus disease 2019 (COVID-19), using the search terms 
“coronavirus”, “COVID-19”, and similar terms, and “mortality”, 
up to March 21, 2020. We found no previous studies of excess 
deaths due to the COVID-19 pandemic. Previous tools and 
models to estimate COVID-19-related deaths have not 
considered the prevalence of underlying conditions, 
background pre-COVID-19 mortality, long-term estimates, 
or the relative impact (relative risk) of COVID-19 on mortality. 
Without these data, it is challenging to predict and prepare 
health systems to respond to the COVID-19 health-care burden.
Added value of this study
We produced a model to estimate the excess COVID-19-related 
mortality by incorporating population infection rate in different 
scenarios relating to degree of social isolation, differing degrees 
of impact of COVID-19 on health systems, and prevalence of 
underlying conditions. We showed that in a full suppression 
scenario, even if COVID-19 has high relative impact on health 
systems, excess mortality over 1 year can be minimised. 
Conversely, with mitigation (ie, less rigorous and voluntary 
measures), we predict between 18 000 and 37 000 deaths. 
We have provided a prototype risk calculator for the researchers 
and policy makers to make estimates and change the 
assumptions in the model. We also highlight the value of 
routine electronic health records and use of large, linked 
datasets at the country level in responding to the pandemic.
Implications of all the available evidence
Our models allow the estimation of overall (direct and indirect) 
effects on excess mortality of the COVID-19 pandemic. For the 
first time, we provide a model, a tool, and open-access data to 
individualise risk prediction across underlying conditions, 
which has clinical, public health, and research benefits for both 
the COVID-19 pandemic and post-pandemic contexts.
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Study population
Eligible individuals were aged 30 years or older and 
registered with a general practice at any point between 
Jan 1, 1997, and Jan 1, 2017, with at least 1 year of follow-up 
data. Demographic characteristics (age, gender, index of 
multiple deprivation quintiles, and geographical region) 
and baseline characteristics (prevalence of underlying 
conditions, risk factors, and medications) were recorded.14 
The overall population at high risk of COVID-19 and 
recommended for physical distancing was defined as per 
Public Health England guidance.12
Open national portal for definitions of underlying 
conditions
We used the Health Data Research (HDR) UK–CALIBER 
open online portal to define underlying conditions from 
records. The underlying conditions were defined using 
Read codes in primary care and the International 
Classification of Diseases 10th edition for hospital 
admissions as per validated CALIBER pheno types.14 
Hypertension was defined on the basis of recorded 
values in primary care according to the most recent 
guidelines (≥140 mm Hg systolic blood pressure [or 
≥150 mm Hg for people aged ≥60 years without 
diabetes and chronic kidney disease] or ≥90 mm Hg 
diastolic blood pressure).16 Diabetes was defined at 
baseline (including type 1, type 2, or uncertain type) on 
the basis of coded diagnoses recorded in Clinical Practice 
Research Datalink or Hospital Episode Statistics at or 
before study entry.15 Severe obesity was defined as body-
mass index of 40 kg/m² or more.16 Cardiovascular disease 
was defined as the 12 most common symptomatic 
manifestations: chronic stable angina, unstable angina, 
myocardial infarction, unheralded death from coronary 
heart disease, heart failure, cardiac arrest or sudden 
coronary death, transient ischaemic attack, ischaemic 
stroke, intracerebral haemorrhage, subarachnoid haem-
or rhage, peripheral arterial disease, and abdominal 
aortic aneurysm, as per previous studies.15–17 COPD and 
chronic kidney disease were defined using previous 
definitions.14–17 Multi morbidity was defined as the co-
occurrence of two or more conditions in an indi vidual.18 
Given recent interest in the potential roles of angiotensin-
converting enzyme (ACE) inhibitors19 and non-steroidal 
inflammatory drugs (NSAIDs),20 we also estimated 
prevalence of their use.
Statistical analysis
To assess prevalent underlying conditions, we only 
included records from the year before baseline (date of 
general practice registration or being aged >30 years 
during the 1997–2017 study period). Follow-up ceased at 
the date of death or on Jan 1, 2017. We estimated prevalence 
of each underlying condition and used Kaplan-Meier 
estimates of 1-year all-cause mortality at each age group 
cell to estimate the number of excess deaths by age bands 
and at each number of conditions cell to estimate by 
number of underlying conditions. We then modelled the 
excess COVID-19-associated mortality for relative impact 
of mortality associated with COVID-19 (relative risk [RR] 
compared with background mortality) of 1·5, 2·0, and 3·021 
at the infection rate consequences of different strategies: 
full suppression (0·001%), partial suppression (1%), 
mitigation (10%), or do nothing (80%).22 Relative risk is a 
comparison of risks or probabilities. For example, an RR 
of 2·0 for COVID-19 describes a doubling of the risk of 
mortality in individuals infected with or affected by 
COVID-19 versus their background risk of death. A 
definition of COVID-19-related mortality relevant to the 
emergency includes both deaths among those infected 
(direct), and deaths among those affected by health service, 
societal, and economic changes (indirect). Considering 
excess deaths in this way, it is reasonable to consider that a 
high proportion (eg, 80% of the population) might be 
affected by the COVID-19 emergency. To extrapolate 
our estimates of excess deaths to the whole population of 
England older than 30 years, we used 2018 estimates of 
overall population size and mortality.23 For illustration, we 
applied our study estimates to UN Population Fund24 
estimates of population size in other countries. All analyses 
were done using R, version 3.4.3. Data were analysed in 
the University College London ISO27001 safe haven.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. LP and SD had full access to all the 
data in the study and AB and HH had final responsibility 
for the decision to submit for publication.
Results
We included 3 862 012 individuals aged 30 years or older. 
1 957 935 (50·7%) were women and 1 904 077 (49·3%) 
For the HDR UK–CALIBER online 
portal see www.caliberresearch.
org/portal
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were men; 3 331 280 (86·3%) were aged 70 years or 
younger (mean age 43·5 years [SD 11·7] in both sexes) 
and 530 732 (13·7%) were older than 70 years (mean age 
78·1 years [6·1] in men and 80·2 years [7·0] in women; 
appendix p 1).
More than 20·0% of the study population had at least 
one high-risk condition defined by Public Health England 
guidelines. 13·7% were older than 70 years and 6·3% 
were aged 70 years or younger with at least one underlying 
condition (figure 1). Age-specific (5-year age bands) and 
sex-specific estimates of prevalence for each underlying 
condition are available online.
Multimorbidity was common (10·1%), especially 
with cardiovascular disease, diabetes, chronic kidney 
disease, and COPD (appendix p 2). In individuals without 
cardio vascular disease (mean age 47·5 years [SD 16·2]), 
diabetes (48·0 years [16·5]), chronic kidney disease 
(48·0 years [16·4]) and COPD (48·2 years [16·6]) 6·7% 
without cardiovascular disease, 7·9% without diabetes, 
9·1% without chronic kidney disease, and 9·7% without 
COPD still had a condition meeting criteria for physical 
distancing. Hypertension was common: 7·4% in the 
individuals aged 70 years or younger and 31·7% in those 
older than 70 years. In individuals aged 70 years or 
younger, prescription of ACE inhibitors was lower (3·7%) 
than in those older than 70 years (14·9%). 14·0% of those 
aged 70 years or younger and 21·1% of those older than 
70 years were prescribed NSAIDs.
Mortality at 1 year was estimated at 4·46% (95% CI 
4·41–4·51) among individuals at high risk. 1-year 
mortality was 8·62% (8·32–8·92) for those with COPD, 
7·84% (7·62–8·06) for those with chronic kidney 
disease, 6·37% (6·25–6·49) for those with cardiovas-
cular disease, and 4·1% (4·0–4·2) for those with 
Figure 2: Baseline 1-year mortality in England according to underlying conditions (n=3 862 012)
n (%)
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Figure 3: Baseline 1-year mortality in England according to number of underlying conditions, age category, and sex (n=3 862 012)
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See Online for appendix
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(Figure 4 continues on next page)
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Figure 4: Estimated number 
of excess deaths at 1 year in 
the UK at different infection 
rates and relative risks for 
the impact of COVID-19
(A) Total deaths. (B) Detailed 
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diabetes (figure 2). Among those older than 70 years, 
1-year mortality rates were 13·6% (12·9–14·3) for 
COPD, 11·5% (11·0–12·1) for chronic kidney disease, 
10·4% (10·1–10·7) for cardio vascular disease, and 8·9% 
(8·5–9·4) for diabetes in men and 12·3% (11·6–13·0) for 
COPD, 9·6% (9·3–10·0) for chronic kidney disease, 
10·6% (10·3–10·9) for cardio vascular disease, and 9·8% 
(9·4–10·2) for diabetes in women.
We estimated baseline 1-year mortality risk by age 
group, sex, and number of conditions, in the absence of 
COVID-19 (figure 3). For example, a man aged 66–70 years 
with no underlying high-risk conditions has a higher 
estimated 1-year mortality risk (1·07%) than a woman 
aged 56–60 years with one underlying condition (0·91%).
According to our online risk calculator, a 66-year-old 
man with COPD has a 6·39% (95% CI 5·48–7·30) 
baseline 1-year mortality risk; thus with 25 641 people in 
England in this subgroup, we projected 1639 baseline 
deaths over 1 year. The model (if set to 10% infection rate 
and RR 2·0) estimates 164 excess COVID-related deaths 
over a year in that demographic category.
At COVID-19 prevalence of 10% (mitigation) and 
80% (do nothing), we estimate the number of excess 
deaths to be 18 374 (mitigation) and 146 996 (do nothing) 
with an RR of 1·5; 36 749 (mitigation) and 293 991 (do 
nothing) with an RR of 2·0; and 73 498 (mitigation) and 
587 982 (do nothing) with an RR of 3·0. Corres ponding 
numbers of deaths at full suppression (0·001%) and 
partial suppression (1%) were two (full) and 1837 (partial) 
with an RR of 1·5; four (full) and 3675 (partial) with an 
RR of 2·0; and seven (full) and 7350 (partial) with an RR 
of 3·0 (figure 4).
Extrapolating from our English sample to the whole UK 
population, we estimate 8·43 million people are in the 
high-risk group, of whom 5·77 million are older than 
70 years of age, and 2·66 million have one or more 
underlying condition and are 70 years or younger). Based 
on the background (pre-COVID-19) 1-year mortality that 
we observed in the CALIBER data of 4·46% for this group, 
376 001 deaths would occur in the UK. Using these 
estimates, numbers of people at high-risk other countries 
were 4·70 million in Canada, 8·31 million in France, 
10·46 million in Germany, 7·51 million in Italy, 
1·28 million in Sweden, and 41·76 million in the USA 
(table).
Discussion
Using NHS records, we provide an initial population-based 
study estimating plausible ranges of excess COVID-19-
related mortality in England. We provide esti mates of 
the prevalence and background (pre-COVID-19) 1-year 
mortality risks according to underlying conditions at dif-
ferent ages in women and men, sharing these estimates 
in online materials, and the disease definitions in the 
HDR UK–CALIBER portal. These are major parameters in 
understanding the emergency, and the best source of 
estimates comes from electronic records, with implications 
for policy makers, clinicians, and the public. Our results 
support rigorous, sustained implementation of suppres-
sion measures.25
With our definition of overall excess deaths, combining 
direct and indirect effects among those with and without 
infection, it is reasonable to consider that a high (eg, 80%) 
proportion of the population might be affected by the 
COVID-19 pandemic. We do not know what the relative 
impact of excess deaths from the COVID-19 pandemic 
will be over a 1-year period in any country. However, 
clinical and societal concern internationally is that it is 
not a regular seasonal flu. We show that if the pandemic 
is associated with an RR of 1·5, then there will 
be 18 374 excess deaths in a mitigation scenario and 
146 996 excess deaths in a do nothing scenario; compared 
with two deaths under a full suppression scenario. A 
doubling of the risk is worth considering because of 
uncertainty regarding the actual risk associated with 
COVID-19 and mounting health-care burden around 
the world. This RR of 2·0 would result in 36 749 excess 
deaths in a mitigation scenario and 293 991 excess deaths 
in a do nothing scenario.
A major concern is that relative risks will rise in a 
non-linear fashion with infection rates if health systems 
become overwhelmed by critically ill patients. Thus, at 
high infection rates, relative risks for excess mortality 
would almost certainly be much higher—and these 
non-linear interactions are a subject for further 
modelling. The impact of COVID-19 is likely to be much 
greater if there is poor compliance with social isolation 
policies and low treatment and health-system capacity. 
The RR of COVID-19 infection and the case fatality rate 
have been estimated,21 but the RR for mortality will 
better capture the impact of infection on individuals 
and health systems. Even in the RR of 2·0 model, full 






High-risk group (millions) Baseline number 
of deaths in 
1 year in 
high-risk group








Total at high 
risk
Canada 37·06 23·44 3·22 1·48 4·70 209 732
England 55·98 35·41 4·87 2·24 7·10 316 805
France 65·50 41·43 5·69 2·62 8·31 370 681
Germany 82·40 52·12 7·16 3·29 10·46 466 322
Italy 59·20 37·45 5·15 2·37 7·51 335 028
Sweden 10·10 6·39 0·88 0·40 1·28 57 158
UK 66·44 42·03 5·77 2·66 8·43 376 001
USA 329·10 208·17 28·60 13·16 41·76 1 862 459
All assumptions are based on England (CALIBER) estimates of 63·25% of the total population older than 30 years, 
13·74% older than 70 years, 6·32% 70 years or younger with an underlying condition, and 20·06% total high-risk 
group; and a 1-year mortality (Kaplan-Meier) for the total high-risk group of 4·46%. 
Table: Projected deaths in 1 year in high-risk group pre-COVID-19 infection across countries
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suppression would lead to virtually no excess mortality, 
because some patients with underlying conditions 
would have died over a 1-year period regardless of the 
COVID-19 outbreak. The prototype online risk calculator 
allows exploration and visualisation of the age-specific, 
sex-specific, and underlying condition-specific excess 
mortality under different assumptions. Near real-time 
cause-specific mortality, as reported by the Office for 
National Statistics, ideally on a weekly basis, will greatly 
aid understanding of the direct and indirect impacts of 
the COVID-19 pandemic.10 Such information can inform 
timing of exit strategies from lockdown. In future 
analyses, the impact of the COVID-19 pandemic on 
disease-specific health-care provision and use should be 
assessed.
We have assumed the same impact (RR) of COVID-19 
on excess mortality for each underlying condition—ie, it 
is the same for a patient with COPD or with morbid 
obesity. Although a reasonable starting point, this 
assump tion requires testing as empirical data become 
available. An interaction between different comorbid-
ities almost certainly exists, meaning that some 
combinations are worse than others, and this factor 
needs to be investigated.
We used a 1-year time period because of concerns 
regarding second waves of infection and the time 
needed for health services and the wider socioeconomic 
disruption to return to a new steady state. Complementary 
future analyses might usefully address the temporal 
resolution (daily and weekly) of excess mortality estimates, 
which are likely to change at different phases of the 
epidemic; specifically to focus on the first 3 months, 
extending to 2 years and beyond.
We show that by Public Health England criteria, at least 
20% of the population falls within the high-risk mortality 
category for COVID-19: 13·7% based on age older than 
70 years (an arbitrary cutoff) and a further 6·3% based on 
having one or more underlying conditions. We show how 
policy might consider age in combination with underlying 
conditions. For example, a man aged 66–70 years with no 
underlying conditions, who is not currently considered 
high risk, has a higher background 1-year mortality (1·07%) 
than that of a woman aged 56–60 years with one underlying 
condition (0·91%), who is considered high risk.
The underlying conditions that we report (cardiovascular 
diseases, COPD, and diabetes) are known to already be 
suboptimally managed before COVID-19, with missed 
opportunities for effective (secondary) preventive inter-
ventions common in many countries.26 With COVID-19 
pressures, these practical actions for clinicians might not 
be addressed, and chronic disease management care 
might deteriorate. Primary and secondary health-care 
workers have an important role in optimising guideline-
recommended management of underlying conditions 
to lower background risk, particularly if shielding or 
suppression measures are to be sustained over long 
periods—eg, 3 or more months. The prototype online 
risk calculator might be relevant for clinicians to prioritise 
such patients.
In England, 1·5 million individuals have been iden-
tified based on national health records as being extremely 
vulnerable to COVID-19 infection, on the basis of one of 
a wide range of factors (including pregnancy with 
serious heart disease, chemotherapy, solid organ 
transplants, and cystic fibrosis).12 These patients have 
been identified and are being individually supported 
(eg, with food parcels and medicine delivery) for the 
life-changing intervention of 12 weeks of shielding. Such 
policies, which require actionable knowledge across 
multiple diseases have few, if any, historical precedents; 
only countries with nationwide health-system data can 
implement such policies. The list was probably designed 
to identify patients who are most susceptible to infection 
or have a degree of immunosuppression, which cannot 
be quantified in a standardised way. The prognosis 
research strategy initiative has previously made recom-
mendations for consistent approaches to understanding 
prognosis across multiple diseases and clinical spe-
cialties, the importance of which is highlighted by the 
COVID-19 pandemic.27
We found that patients with conditions not on the 
vulnerable patient list may be at as high or greater 
mortality than those who are. For example, cardiovascular 
disease is not on the vulnerable patient list and has a 
1-year mortality of 6%; we found that the 1-year mortality 
risk of people with two or more conditions was 11%—
but multiple morbidities co-occurring in the same 
individual do not yet qualify as extremely vulnerable. A 
more systematic, transparent understanding is needed 
of which underlying conditions are important for policy 
and patients. Further research is required to identify the 
extent to which patients with other physical conditions, 
frailty, and mental health conditions as well as those 
experiencing social exclusion (eg, homeless people and 
intravenous drug users) might benefit from targeted 
interventions.
We have deposited definitions of underlying conditions 
relevant to COVID-19 in the HDR UK–CALIBER open 
online portal. It is important for reproducible research 
in COVID-19 that different research groups within 
and between countries use clinical information from 
electronic health records in consistent, transparent, 
and validated ways to define underlying conditions and 
the COVID-19 syndrome (electronic health record 
phenotypes). It has previously been shown that in 
defining one disease—asthma—research groups com-
bine clinical data in more than 60 different ways to reach 
a definition.28 However, few efforts have been made to 
harmonise definitions of diseases across national 
electronic health records. To address the COVID-19 
pandemic, international efforts are needed to harmonise 
definitions of underlying conditions and the clinical 
syndrome and progression of COVID-19 infection using 
routine clinical health records.
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We share age-specific (5-year age bands) and sex-
specific estimates of prevalence and 1-year mortality for 
each underlying condition. These population-based esti-
mates might be relevant for other countries, particularly 
those in which population-based records are neither 
available nor accessible. As an illustration, we show 
estimates of excess deaths in different countries if the 
background (pre-COVID-19) mortality from England 
were applied. It is known, based on disease-specific 
registries, that mortality among people with underlying 
conditions differs between countries, but few studies 
using electronic health records compare outcomes across 
countries. In one study, the long-term mortality among 
patients who had survived a heart attack was broadly 
consistent across France, Sweden, the UK, and the USA,29 
suggesting that our findings might have international 
relevance.
Like other researchers, we were able to access only a 
sample of relevant NHS data, covering 5% of the UK 
population, excluding any detailed information from 
hospitals. Research is a key part of the COVID-19 
response, and the UK Government is already acting to 
increase publicly accountable access to NHS health 
and social care data to a large number of researchers, 
clinicians, and policy makers nationwide. Currently 
researchers can access only small samples, in which 
linkage to even simple data on hospital admissions 
requires multiple approvals and can take years. It is 
impossible to access NHS data on the COVID-19 
epidemic as a nationwide whole (it is fragmented by 
primary and secondary care and across countries). 
Despite small networks for critical care,30 and coronary 
disease,31 there are currently no national efforts to stream 
real-time, actionable data on COVID-19 care and (non-
fatal) outcomes. With public and Government support, 
the NHS has an opportunity to mobilise its data to create 
a learning health system needed urgently for COVID-19, 
in which high-quality clinical information is collected. 
A system like this would need to include measures of 
disease severity, which are often absent. Beyond the 
COVID-19 pandemic, this system could have far-
reaching, long-term benefits for patient care by 
accelerating knowledge generation and application.
We might have underestimated true 1-year mortality 
risks because physical distancing policies might them-
selves influence the background mortality risks—people 
might be less likely to access health and social care, and 
physical isolation has in many previous studies been 
shown to be associated with the onset and progression of 
cardio vascular and other diseases. Underlying diseases, 
treatment, and health-care use need to be explored in 
detail in the context of COVID-19. It is not known 
whether sudden and systematic physical distancing,32 
particularly if prolonged over months, has different 
or additional health consequences from those reported 
from earlier studies of isolation. Understanding how 
to mitigate the emergency will require accessing and 
linking data about causes and consequences of the 
emergency across sectors, including education, economy, 
and transport.
We have presented our findings in a way that begins to 
be understandable by the general public, because of calls 
for information that might be relevant to an individual’s 
risk—here defined by age, sex, and presence of an 
underlying condition.1 No authoritative public-facing tools 
are yet available, but they might provide context, motivation, 
and support to comply with the multiple changes in daily 
living that shielding entails. Particularly over prolonged 
isolation, this could be important given concern about the 
practical ability of patients to maintain shielding.
By contrast with the daily news feed in every country, 
which reports the numbers of deaths (the numerator), we 
report a risk: numbers of deaths over 1 year divided by the 
population who was at risk of dying. Among the public it 
might not be widely appreciated that 1400 people die on 
average every day in the UK at baseline (ie, before 
COVID-19).33 Of all those people dying within 1 year, it is 
likely that COVID-19 brings forward the death earlier in 
the year. In other words, there are competing causes for 
the mortality.
Our study has important limitations. The study was 
developed over a 72-h period before posting the results on 
March 22, 2020, the day before the UK Prime Minister 
announced lockdown. First, our models require further 
data for their development. Commonly, research using 
NHS data can take months, and even years, partly because 
of the multiple steps in accessing such data for research. 
Specifically, it is important to study a wider range of 
underlying conditions, a wider range of hospital and 
critical care admissions, linkage of primary care data to 
nationally available information on COVID-19 testing, 
linkage to richer, real-time hospital data, and use of 
nationwide NHS data. Second, we believe it is both a 
limitation and a strength that our model is simple and 
supports public understanding. The assumptions we 
make can be tested as empirical data become available, 
such as the Office for National Statistics data.10 There 
are many avenues for further modelling to better 
understand how to target different preventive interven-
tions. An (incomplete) list includes statistical (dynamic 
models, weekly rates of mortality, and competing risks), 
public health (disease-specific data for high-risk and 
extremely vulnerable conditions, regional variation, social 
depri vation, and ethnicity), clinical (including hospital 
and critical care admissions), and health service factors 
(including data on health-care workers and operational 
features).
Health-care professionals, like those involved in this 
paper, are being redirected to provide priority clinical 
services during the emergency internationally. We 
believe an important aspect of emergency response is to 
support clinical academics to continue to contribute to 
research into new preventive and treatment options, as 
they take on new service responsibilities.
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If the relative risk of COVID-19 on mortality over 1 year 
were 1·2 (ie, the same magnitude as the winter vs summer 
mortality excess) then the number of excess deaths would 
be zero when one in 100 000 individuals are infected (full 
suppression scenario), 7350 when one in ten are infected 
(mitigate scenario), and 58 798 when eight in ten are 
infected (do nothing scenario). However, if the relative risk 
is doubled to 2·0, then there would be 36 749 deaths in the 
mitigation scenario and 293 991 deaths in the do nothing 
scenario. These results should inform targeting of those at 
highest risk for a range of preventive interventions.
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